|By PR Newswire||
|April 3, 2014 01:30 AM EDT||
SAN DIEGO and HILDEN, Germany, April 3, 2014 /PRNewswire/ --
- New innovative product launches at American Association for Cancer Research (AACR) Annual Meeting add to broad portfolio of NGS solutions
- High-speed QIAxpert accelerates quantification and quality control of nucleic acids with easy-to-use software and analysis aiding sample-to-insight workflows
- CLC Cancer Research Workbench is the world's first comprehensive, user-friendly and customizable cancer-focused NGS bioinformatics solution
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced two important new product launches which address workflow challenges in next-generation sequencing (NGS) applications. QIAGEN will present these and several other innovative solutions for NGS applications at the American Association for Cancer Research (AACR) Annual Meeting from April 5-9 in San Diego, with about 35 poster and other sessions featuring applications of QIAGEN's Sample & Assay Technologies.
The innovative QIAxpert® instrument accelerates quantification and quality control of DNA and RNA samples for next-generation sequencing (NGS), while the new CLC Cancer Research Workbench is the first complete bioinformatics software suite for rapid analysis, user-friendly visualization, and accurate interpretation of advanced NGS data in cancer research.
"Our portfolio of universal products for NGS includes innovative solutions for many of the key workflow challenges our customers face in sample preparation. QIAxpert and QIAxcel can assure the highest sample quality, saving time and costs by reducing the risk of having to repeat NGS experiments, and thus helping laboratories to generate valuable insights," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "In addition, our industry-leading bioinformatics portfolio is providing a new dimension of utility for our customers, as our commercial software solutions offer highest quality and performance, helping to accelerate NGS workflows and remove variability. The new CLC Cancer Research Workbench offers scientists and clinicians state-of-the-art analysis and interpretation of gene variants and cancers. At AACR, we will show these products plus new data for our GeneRead™ gene panels - all of which maximize NGS performance for all major platforms."
QIAxpert is a high-speed UV/VIS spectrophotometer that enables laboratories to effortlessly assess the quality and quantity of nucleic acids in up to 16 samples within just two minutes. The QIAxpert employs intuitive software and an interactive touchscreen. Pre-installed smart analysis applications can quantify both DNA and RNA with advanced spectral protocols to accurately differentiate molecules in complex samples, providing a comprehensive analytical profile. QIAxpert aligns well with QIAxcel, QIAGEN's capillary electrophoresis platform for DNA/RNA fragment analysis, ensuring the best quality in nucleic acid sample preparation for NGS.
The CLC Cancer Research Workbench is the world's first comprehensive, cancer-focused bioinformatics solution that can be modified or personalized by researchers. Its user-friendly software enables researchers to identify prognostic markers, identify sub-clonal somatic mutations, detect inherited traits, find biomarkers for drug response, and determine new oncogenes. Advanced re-sequencing tools, in combination with an intuitive graphical user interface, provide rapid analysis and accurate interpretation of advanced NGS data. The CLC Cancer Research Workbench also enables all results to be filtered, visualized, and compared with relevant databases like COSMIC, ClinVar, or in-house curated ones, as well as with other datasets, in order to provide valuable insights and guide user research.
QIAGEN spotlight presentation at the AACR meeting
At the AACR meeting, QIAGEN will host an exhibitor spotlight presentation, "Revolutionize Your NGS Workflow with QIAGEN's Platform-Agnostic Sample to Insight Solution," from 10-11 a.m. on Tuesday April 8 in Exhibit Hall A of the San Diego Convention Center. The workshop will offer new data on the ability of the GeneRead™ panels to identify known and novel mutations in paired tumor and normal formalin-fixed paraffin-embedded samples.
To learn more about QIAGEN's presence at AACR, please visit http://www.qiagen.com/landing-pages/aacr-2014 or follow the Twitter handle @QIAGENscience during the conference. For more information on QIAxpert, visit http://www.qiagen.com/search/qiaxpert-system. To learn more about the CLC Cancer Research Workbench, visit http://clccancer.com/software/.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2013, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at http://www.QIAGEN.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Dr. Thomas Theuringer
Director Public Relations
Email: [email protected]
Vice President Corporate Communications and Investor Relations
Email: [email protected]
Technology vendors and analysts are eager to paint a rosy picture of how wonderful IoT is and why your deployment will be great with the use of their products and services. While it is easy to showcase successful IoT solutions, identifying IoT systems that missed the mark or failed can often provide more in the way of key lessons learned. In his session at @ThingsExpo, Peter Vanderminden, Principal Industry Analyst for IoT & Digital Supply Chain to Flatiron Strategies, will focus on how IoT depl...
Jan. 18, 2017 02:30 AM EST Reads: 1,812
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at Dell EMC, introduced a methodology for capturing, enriching and sharing data (and analytics) across the organization...
Jan. 18, 2017 02:15 AM EST Reads: 3,205
With all the incredible momentum behind the Internet of Things (IoT) industry, it is easy to forget that not a single CEO wakes up and wonders if “my IoT is broken.” What they wonder is if they are making the right decisions to do all they can to increase revenue, decrease costs, and improve customer experience – effectively the same challenges they have always had in growing their business. The exciting thing about the IoT industry is now these decisions can be better, faster, and smarter. Now ...
Jan. 18, 2017 01:30 AM EST Reads: 4,199
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
Jan. 18, 2017 01:15 AM EST Reads: 4,876
"Splunk basically takes machine data and we make it usable, valuable and accessible for everyone. The way that plays in DevOps is - we need to make data-driven decisions to delivering applications," explained Andi Mann, Chief Technology Advocate at Splunk and @DevOpsSummit Conference Chair, in this SYS-CON.tv interview at @DevOpsSummit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Jan. 18, 2017 01:00 AM EST Reads: 2,012
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
Jan. 18, 2017 01:00 AM EST Reads: 6,045
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
Jan. 18, 2017 12:45 AM EST Reads: 5,950
"Logz.io is a log analytics platform. We offer the ELK stack, which is the most common log analytics platform in the world. We offer it as a cloud service," explained Tomer Levy, co-founder and CEO of Logz.io, in this SYS-CON.tv interview at DevOps Summit, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Jan. 18, 2017 12:45 AM EST Reads: 6,251
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captur...
Jan. 18, 2017 12:30 AM EST Reads: 2,785
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Jan. 18, 2017 12:00 AM EST Reads: 2,258
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, when the pain caused by the exponential complexity becomes apparent. We've seen this problem occur time and time again. In his session at Big Data Expo, Greg Bruno, Vice President of Engineering and co-founder of StackIQ...
Jan. 18, 2017 12:00 AM EST Reads: 7,740
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
Jan. 17, 2017 11:30 PM EST Reads: 4,357
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
Jan. 17, 2017 11:15 PM EST Reads: 4,941
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, John Jelinek IV, a web developer at Linux Academy, will discuss why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers...
Jan. 17, 2017 11:00 PM EST Reads: 607
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal ...
Jan. 17, 2017 10:30 PM EST Reads: 2,369